Autobio Diagnostics Co., Ltd (Hereinafter called Autobio)(603658.SH) released the third quarter report：the first three quarters of this year's total sale is CNY 2.695 billion, up 31.64% year on year. Net profit attributable to shareholders of listed companies reached was CNY 717 million, up 39.33% year-on-year.

Autobio Diagnostics Co., Ltd (Hereinafter called Autobio) was founded in 1998, headquartered in National Eco & Tech Zone, Zhengzhou. Autobio specialized in R & D, production, marketing and service of clinical diagnostic products, especially covering immunoassay, microbiology and biochemistry fields. Meanwhile, Autobio is also actively planning the developments in the field of molecular diagnostics and provides a comprehensive solutions for medical laboratories. Autobio was listed on Shanghai Stock Exchange on September 1st, 2016, which is the first IVD manufacturer listed on the main board in Shanghai,China.

In 2019, Autobio’s revenue achieved USD 412 millions, a year-on-year increase of 38.85%; in 2020, Autobio’s revenue achieved USD 459 millions.